Topics

Presage and Celgene Collaborate to Investigate Novel Agents with CIVO Technology

15:27 EDT 2 May 2019 | Speciality Pharma Journal

SEATTLE, May 2, 2019 /PRNewswire/ — Presage Biosciences, a cancer biotechnology company pioneering a new cancer drug development approach using its CIVO™ intratumoral microdosing platform, today announced it has entered into a research collaboration with Celgene Corporation to evaluate several of Celgene’s early stage assets in Phase 0 trials. Presage’s CIVO platform is used to evaluate patients’ unique …

Original Article: Presage and Celgene Collaborate to Investigate Novel Agents with CIVO Technology

NEXT ARTICLE

More From BioPortfolio on "Presage and Celgene Collaborate to Investigate Novel Agents with CIVO Technology"

Quick Search

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...